Immunogenicity and Safety of a High-Dose Quadrivalent Influenza Vaccine Administered by the Intramuscular Route in Subjects 60 Years of Age and Older
Latest Information Update: 06 Oct 2023
At a glance
- Drugs Influenza virus vaccine (Primary) ; Influenza vaccine quadrivalent Abbott Biologicals
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Sanofi Pasteur
- 29 Jun 2020 Status changed from recruiting to completed.
- 15 Jun 2020 Planned End Date changed from 1 May 2020 to 1 Jun 2020.
- 22 Aug 2019 Status changed to recruiting.